炎症预后指数:一种新的预测器,用于在药物排泄的支架-皮肤冠状动脉干预后的支架内静脉缩
Cemre Turgul1, Saban Kelesoglu2
1Department of Cardiology, University of Health Sciences, Kayseri City Training and Research Hospital, Kayseri 38 000, Turkey.
Diagnostics (Basel, Switzerland)
|March 14, 2026
概括
新的炎症预后指数 (IPI) 在植入药物释放支架 (DES) 后有效预测支架内静止症 (ISR). 这种简单的生物标志物,使用常规实验室测试,有助于冠状动脉疾病风险分层.
科学领域:
- 心脏病学 心脏病学
- 生物标志物研究 生物标志物研究
- 炎症研究 炎症研究
背景情况:
- 系统性炎症和营养状况在静止静止症 (ISR) 中至关重要.
- 炎症预后指数 (IPI) 整合了C反应蛋白 (CRP),白蛋白和中性粒细胞与淋巴细胞的比率 (NLR) 来评估炎症和营养.
研究的目的:
- 评估IPI在植入药物排泄支架 (DES) 后预测ISR方面的预后价值.
- 确定IPI是否可以作为在接受DES手术的患者中风险分层的简单且具有成本效益的生物标志物.
主要方法:
- 对571名接受了DES植入和随访血管造影的患者进行了回顾性分析.
- 使用公式计算IPI: (CRP × NLR) / 专辑蛋白.
- 后勤回归和接收器操作特征 (ROC) 分析,以评估IPI对ISR的预测能力.
主要成果:
- 在研究队列中,在38.1%的患者中观察到静脉静脉缩 (ISR).
- 升高的IPI是ISR的一个独立预测因素 (OR = 2.90;95% CI = 2.35-3.57;p < 0.001).
- 最佳IPI截止值为1.275表明ISR预测的高灵敏度 (84.4%) 和特异性 (74.5%).
结论:
- IPI是DES植入后ISR的独立预测器.
- 从常规实验室检测中计算的IPI提供了一种简单且廉价的方法,用于冠状动脉疾病的风险分层.
- 这种生物标志物有可能改善患者管理,并识别ISR风险较高的个体.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
580
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
580
01:28Acute Coronary Syndrome IV: Interprofessional Care
376
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
376